Healthcare
Wave Life Sciences Ltd.(WVE)
Live Price
Offline$6.16
+3.53% today
1Y Change
-18.10%
Window
Jun 23, 2025 โ Jun 8, 2026
- Market Cap
- $1.44B
- Revenue Growth
- -60.5%
- EPS Growth
- -72.9%
- Dividend Yield
- 0.0%
Coverage: 241 bars ยท Jun 23, 2025 โ Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wave Life Sciences Ltd. (WVE) is a Healthcare stock with a market cap of $1.44B and listed on NASDAQ. The stock last traded around $6.16 and down 18.1% across the available one-year price window (Jun 23, 2025 โ Jun 8, 2026). Baseline metrics include revenue growth of -60.5%, EPS growth of -72.9%, a dividend yield of 0.0%. What stands out right now is revenue -60.5%, EPS -72.9%, free cash flow -23.4% with operating margin -274.2% and ROIC -36.3%. Valuation already assumes a fairly strong business story at price/sales 20.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WVE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-60.5% vs +7.6% peer median
Operating Margin
Below sector median
-274.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -60.5% and EPS is at -72.9%, with operating margin around -274.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.9% | -7.0% | โ |
2026 Feb 26, 2026 | -7.1% | -9.3% | -14.1% | -59.6% |
2025 Nov 10, 2025 | -6.7% | +3.0% | +1.4% | +202.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WVE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WVE Max Drawdown
-73.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WVE and SPY.
Company Overview
Wave Life Sciences Ltd.
NASDAQ Global Market
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
- Leadership
- Paul Bolno
- IPO Date
- Nov 11, 2015
- Employees
- 287
- Street Address
- Marina One East Tower
- Mailing
- Singapore, 018936
- Region
- Singapore, SG
- Reporting Currency
- USD
- Investor Line
- 65 6236 3388
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 20.0
- Price/Book
- 2.9
Growth
- Revenue
- -60.5%
- EPS
- -72.9%
- Free Cash Flow
- -23.4%
Profitability
- Gross Margin
- 93.8%
- Operating Margin
- -274.2%
- Net Margin
- -255.7%
- ROE
- -56.4%
- ROIC
- -36.3%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 11.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.